The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 12, 2016, Pages 2003-2011

  Cisek, Katryna ^a   Krochmal, Magdalena ^b,c   Klein, Julie ^d,e   Mischak, Harald ^a,f  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b Academy of Athens Biomedical Research Foundation   (Greece)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d INSERM   (France)

^e UNIVERSITÉ PAUL SABATIER   (France)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

chronic kidney disease; data integration; omics; systems biology; therapeutic target

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; BIOLOGY; CHRONIC KIDNEY FAILURE; FACTUAL DATABASE; GENETICS; GENOMICS; HUMAN; METABOLISM; METABOLOMICS; PATHOLOGY; PROCEDURES; PROTEOMICS; SYSTEMS BIOLOGY;

ANIMALS; BIOMARKERS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; GENOMICS; HUMANS; METABOLOMICS; PROTEOMICS; RENAL INSUFFICIENCY, CHRONIC; SYSTEMS BIOLOGY;

EID: 85027467019     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv364     Document Type: Review

References (52)

1. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696
2. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365
3. Ortiz A, Covic A, Fliser D et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831-1843
4. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033
5. Mischak H, Delles C, Vlahou A et al. Proteomic biomarkers in kidney disease: issues in development and implementation. Nat Rev Nephrol 2015; 11: 221-232
6. Little MH, Brown D, Humphreys BD et al. Defining kidney biology to understand renal disease. Clin J Am Soc Nephrol 2014; 9: 809-811
7. Becker GJ, Hewitson TD. Animal models of chronic kidney disease: useful but not perfect. Nephrol Dial Transplant 2013; 28: 2432-2438
8. Herget-Rosenthal S. Imaging techniques in the management of chronic kidney disease: current developments and future perspectives. Semin Nephrol 2011; 31: 283-290
9. Mischak H, Allmaier G, Apweiler R et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010; 2: 46ps42
10. Filip S, Pontillo C, Peter Schanstra J et al. Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. Expert Rev Proteomics 2014; 11: 535-548
11. Klein J, Jupp S, Moulos P et al. The KUPKB: a novel web application to access multiomics data on kidney disease. FASEB J 2012; 26: 2145-2153
12. Komorowsky CV, Brosius FC, Pennathur S et al. Perspectives on systems biology applications in diabetic kidney disease. J Cardiovasc Translat Res 2012; 5: 491-508
13. Mayer P, Mayer B, Mayer G. Systems biology building a useful model from multiple markers and profiles. Nephrol Dial Transplant 2012; 27: 3995-4002
14. Wilmes A, Limonciel A, Aschauer L et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics 2013; 79: 180-194
15. Nkuipou-Kenfack E, Bhat A, Klein J et al. Identification of ageingassociated naturally occurring peptides in human urine. Oncotarget 2015; in press
16. Zhang AD, Dai SX, Huang JF. Reconstruction and analysis of human kidney-specific metabolic network based on omics data. BioMed Research International 2013; 2013: 1-11
17. Pontillo C, Filip S, BorrasDMet al. CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl 2015; 9: 322-334
18. Lamb J, Crawford ED, Peck D et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935
19. Martini S, Eichinger F, Nair V et al. Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord 2008; 9: 267-274
20. Heinzel A, Mühlberger I, Stelzer G et al. Molecular disease presentation in diabetic nephropathy. Nephrol Dial Transplant 2015; 30(Suppl 4): iv17-iv25
21. Hamon J, Jennings P, Bois FY. Systems biology modeling of omics data: effect of cyclosporine a on the NRF2 pathway in human renal cells. BMC Syst Biol 2014; 8: 76
22. He L, Sun Y, Takemoto M et al. The glomerular transcriptome and a predicted protein-protein interaction network. J Am Soc Nephrol 2008; 19: 260-268
23. Husi H, Van Agtmael T, Mullen Wet al. Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circ Cardiovasc Genet 2014; 7: 161-170
24. Perco P, Muhlberger I, Mayer G et al. Linking transcriptomic and proteomic data on the level of protein interaction networks. Electrophoresis 2010; 31: 1780-1789
25. Song X, Di GV, He N et al. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 2009; 18: 2328-2343
26. Woroniecka KI, Park AS, Mohtat D et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011; 60: 2354-2369
27. Yagil C, Hubner N, Monti J et al. Identification of hypertension-related genes through an integrated genomic-transcriptomic approach. Circ Res 2005; 96: 617-625
28. Heinzel A, Perco P, Mayer G et al. From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action. Front Cell Dev Biol 2014; 2: 37
29. Sirota M, Dudley JT, Kim J et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77
30. Deans AR, Lewis SE, Huala E et al. Finding our way through phenotypes. PLoS Biol 2015; 13: e1002033
31. Bruggeman FJ, Westerhoff HV. The nature of systems biology. Trends Microbiol 2007; 15: 45-50
32. ChenWC, Tzeng YS, Li H.Gene expression in early and progression phases of autosomal dominant polycystic kidney disease. BMC Res Notes 2008; 1: 131
33. Al-RubeaiM, Fussenegger M. Systems Biology. Dordrecht, The Netherlands: Springer, 2007; 1-433
34. Gomez-Cabrero D, Abugessaisa I, Maier D et al. Data integration in the era of omics: current and future challenges. BMC Syst Biol 2014; 8: I1
35. GreenbaumD, Colangelo C, Williams K et al. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003; 4: 117
36. Bernthaler A, Muhlberger I, Fechete R et al. A dependency graph approach for the analysis of differential gene expression profiles. Mol Biosyst 2009; 5: 1720-1731
37. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013; 41: D377-D386
38. Fechete R, Heinzel A, Söllner J et al. Using information content for expanding human protein coding gene interaction networks. J Comput Sci Syst Biol 2013; 6: 073-082
39. Robinson SW, Fernandes M, Husi H. Current advances in systems and integrative biology. Comput Struct Biotechnol J 2014; 11: 35-46
40. Lambers Heerspink HJ, Oberbauer R, Perco P et al. Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrol Dial Transplant 2015; 30: 105-112
41. Schmid A, Blank LM. Systems biology: hypothesis-driven omics integration. Nat Chem Biol 2010; 6: 485-487
42. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011; 12: 56-68
43. Moulos P, Klein J, Jupp S et al. The KUPNetViz: a biological network viewer for multiple-omics datasets in kidney diseases. BMC Bioinformatics 2013; 14: 235
44. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res 2007; 17: 1520-1528
45. Larance M, Lamond AI. Multidimensional proteomics for cell biology. Nat Rev Mol Cell Biol 2015; 16: 269-280
46. Nabieva E, Jim K, Agarwal A et al. Whole-proteome prediction of protein function via graph-theoretic analysis of interaction maps. Bioinformatics 2005; 21(Suppl 1): i302-i310
47. Bordbar A, Feist AM, Usaite-Black R et al. A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol 2011; 5: 180
48. Saha R, Chowdhury A, Maranas CD. Recent advances in the reconstruction of metabolic models and integration of omics data. Curr Opin Biotechnol 2014; 29: 39-45
49. Lock E, Ranganath LR, Timmis O. The role of nitisinone in tyrosine pathway disorders. Curr Rheumatol Rep 2014; 16: 457
50. Lambers Heerspink HJ, de Zeuuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013; 76: 536-550
51. Loscalzo J, Barabasi AL. Systems biology and the future of medicine.Wiley Interdiscip Rev Syst Biol Med 2011; 3: 619-627
52. Glorieux G, Mullen W, Duranton F et al. New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol Dial Transplant 2015; 30: 1842-1852